Less is More for TNFi Dosing in Axial Spondyloarthritis

Researchers writing in Arthritis Research and Therapy describe the results of a randomized clincal trial in which most patients with Ankylosing spondylitis maintained low disease activity or remission with standard or reduced TNFi dose schedules.

References:

Jordi Gratacos, Caridad Pontes, Xavier Juanola, et al. Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis. Arthritis Research & Therapy (2019) 21:11. https://doi.org/10.1186/s13075-018-1772-z